The Filing Desk

Opus Genetics

IRD · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

IRD · Last close · November 19, 2026
$4.08
Value Opus Genetics yourself

Opus Genetics' revenue rose 29.1% to $14 million in fiscal 2025. Its operating margin was −271.9%, up from −564.7% a year earlier. The diluted share count rose 132.9%.

Opus Genetics, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 12, 2026 · 0001140361-26-009247 Updated
Revenue
$14M
29.1%
Operating margin
−271.9%
292.8 pts
Net income
−$50M
 
Free cash flow
—
 
Return on equity
−449.4%
246.2 pts
Market cap
$415M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Opus Genetics does

Opus Genetics is a clinical-stage drug company developing gene therapies to restore vision and prevent blindness in people with inherited retinal diseases, which are genetic conditions that damage the light-sensing tissue at the back of the eye. Its gene therapies are meant to be one-time treatments that address the genetic cause.

Its pipeline has seven gene therapy programs that use adeno-associated virus (AAV) vectors to deliver genes into cells. The lead programs are OPGx-LCA5 and OPGx-BEST1, and others target the genes RHO, CNGB1, RDH12, NMNAT1 and MERTK. It also has Phentolamine Ophthalmic Solution 0.75%, an eye drop approved by the FDA to reverse pharmacologically induced dilation of the pupil, which it is studying for other uses such as presbyopia, the loss of near vision with age.

The company licensed that eye drop to Viatris, which launched it in April 2024 under the brand name RYZUMVI. Opus was founded in 2018 as Ocuphire Pharma, and it took its current form after acquiring a gene therapy company in October 2024. It says it has no sales or marketing system of its own.

Its biggest risks, as it describes them

  • It has not earned significant revenue from product sales and expects losses for the foreseeable future.
  • It will need substantial additional capital, and raising it may dilute shareholders.
  • Its gene therapies use new technology that is hard to develop and make, and trials may fail or be delayed.
  • It depends heavily on its pipeline and on finding strategic partners, and has no sales infrastructure of its own.
From Opus Genetics's annual report on Form 10-K, filed March 12, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Opus Genetics lost money in fiscal 2025: a net loss of $50 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments2543503045
Debt incl. finance leases———01
Net debt (negative means net cash)———−30−44
Net debt to EBITDA—————
Debt to equity———0.0x0.1x
Interest coverage−11,352.5x2,025.1x——−299.2x
Current ratio6.8x17.8x13.3x3.2x6.4x
Quick ratio6.8x17.8x13.3x3.2x6.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Opus Genetics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $323,890 of Opus Genetics shares on the open market, and 7 insiders sold $16.6 million, $127,120 of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 3, 2026Robert E. GagnonChief Financial OfficerSold plan28,000$4.54$127,120Form 4
Jul 23, 2026George MagrathChief Executive Officer, DirectorSold9,475$2.95$27,951Form 4
Jul 23, 2026Robert E. GagnonChief Financial OfficerSold7,783$2.95$22,960Form 4
Jul 23, 2026Benjamin R YerxaPresident, DirectorSold7,429$2.97$22,064Form 4
Jul 23, 2026Joseph K SchachleChief Operating OfficerSold4,644$2.94$13,653Form 4
May 18, 2026Foundation Fighting Blindness Retinal Degeneration FundDirectorSold1,700,000$4.35$7.4 millionForm 4
Apr 23, 2026George MagrathChief Executive Officer, DirectorSold9,511$5.22$49,647Form 4
Apr 23, 2026Robert E. GagnonChief Financial OfficerSold7,842$5.18$40,622Form 4
Apr 23, 2026Ashwath JayagopalChief Scientific & Dev. Ofc.Sold7,542$5.19$39,143Form 4
Apr 23, 2026Benjamin R YerxaPresident, DirectorSold7,470$5.24$39,143Form 4
Apr 23, 2026Joseph K SchachleChief Operating OfficerSold4,697$5.22$24,518Form 4
Apr 23, 2026Rabourn Amy ZarembaHead of Fin. Quality AssuranceSold1,641$5.20$8,533Form 4
The latest 12 of 18 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score——3 of 8
Rule of 40———
Altman Z''12.79−18.48−11.42
Accruals ratio−17.2%−70.4%−32.9%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets——Fail
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailFailPass
F-score——3 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Opus Genetics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Opus GeneticsFY2529.1%−271.9%———3
Pyxis OncologyFY25−14.2%−609.2%−458.3%———Compare
Tonix PharmaceuticalsFY2529.9%−959.0%−787.5%———Compare
EvommuneFY2585.7%−623.6%−589.8%———Compare
ProQR TherapeuticsFY25−15.9%−273.1%−338.3%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue———30140191114
Revenue growth————−100.0%—6,665.7%−52.2%−42.3%29.1%
Gross profit——————————
Research and development101113671514182731
Operating income−16−17−20−4−20−2318−11−62−39
Net income−9−25−14−6−25−5718−10−58−50
Diluted EPS (US$)−0.43−0.92−5.25−2.17−5.28−3.820.87−0.46−2.15−0.80
Diluted shares (millions)22273351521222762
Cash flow
Cash from operations−13−15−19−4−7−1914−1−26−35
Capital expenditure———00—————
Free cash flow———−4−7—————
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation1110222433
Balance sheet at fiscal year end
Cash and short-term investments129912162543503045
Debt incl. finance leases————————01
Total assets2128162182649543750
Total liabilities41269314341135
Shareholders' equity1717−2−8−14224650715
Margins and ratios
Gross margin——————————
Operating margin———−139.8%—−3,854.8%45.7%−55.5%−564.7%−271.9%
Net margin———−205.6%—−9,625.3%44.9%−52.4%−523.4%−349.3%
Free cash flow margin———−120.6%——————
Rule of 40 (growth + FCF margin)——————————
Return on capital——————————
Return on equity−52.0%−149.6%−190.7%——−1,295.1%52.3%−20.8%−203.2%−449.4%
Return on assets−40.6%−102.5%−64.8%−69.2%−252.9%−259.1%47.7%−19.4%−126.7%−113.9%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Opus Genetics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Opus Genetics.